ScoreWhy is ImmuCell Corp. ?
1
Poor Management Efficiency with a low ROCE of 0.87%
- The company has been able to generate a Return on Capital Employed (avg) of 0.87% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Operating profit has grown by an annual rate 34.00% of over the last 5 years
- PRE-TAX PROFIT(Q) At USD -0.12 MM has Fallen at -122.28%
- NET PROFIT(Q) At USD -0.12 MM has Fallen at -121.96%
- RAW MATERIAL COST(Y) Grown by 22.94% (YoY)
3
With ROE of 7.80%, it has a risky valuation with a 1.99 Price to Book Value
- Over the past year, while the stock has generated a return of 61.13%, its profits have risen by 160.9% ; the PEG ratio of the company is 0.2
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is ImmuCell Corp. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
ImmuCell Corp.
61.13%
2.57
51.73%
S&P 500
15.76%
1.20
13.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
12.77%
EBIT Growth (5y)
34.00%
EBIT to Interest (avg)
-1.93
Debt to EBITDA (avg)
1.67
Net Debt to Equity (avg)
0.21
Sales to Capital Employed (avg)
0.60
Tax Ratio
4.06%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
18.41%
ROCE (avg)
0.87%
ROE (avg)
0.66%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
26
Industry P/E
Price to Book Value
1.99
EV to EBIT
27.94
EV to EBITDA
12.92
EV to Capital Employed
1.83
EV to Sales
2.34
PEG Ratio
0.17
Dividend Yield
NA
ROCE (Latest)
6.56%
ROE (Latest)
7.80%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend6What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 5.89 MM
NET PROFIT(HY)
Higher at USD 1.83 MM
DEBT-EQUITY RATIO
(HY)
Lowest at 11.43 %
-12What is not working for the Company
PRE-TAX PROFIT(Q)
At USD -0.12 MM has Fallen at -122.28%
NET PROFIT(Q)
At USD -0.12 MM has Fallen at -121.96%
RAW MATERIAL COST(Y)
Grown by 22.94% (YoY
OPERATING PROFIT(Q)
Lowest at USD 0.41 MM
OPERATING PROFIT MARGIN(Q)
Lowest at 5.64 %
Here's what is working for ImmuCell Corp.
Operating Cash Flow
Highest at USD 5.89 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Debt-Equity Ratio
Lowest at 11.43 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Here's what is not working for ImmuCell Corp.
Pre-Tax Profit
At USD -0.12 MM has Fallen at -122.28%
over average net sales of the previous four periods of USD 0.54 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -0.12 MM has Fallen at -121.96%
over average net sales of the previous four periods of USD 0.53 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Operating Profit
Lowest at USD 0.41 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (USD MM)
Operating Profit Margin
Lowest at 5.64 %
in the last five periodsMOJO Watch
Company's profit margin has deteriorated
Operating Profit to Sales
Raw Material Cost
Grown by 22.94% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
Footer loading
